NCT01973387 – A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Posted on May 8, 2024 by Maryam Hussain -
NCT01578707 – A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Posted on August 5, 2023 by tsuperadmin -
NCT01611090 – Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton’s Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Posted on February 4, 2022 by tsuperadmin -
NCT01105247 – A Phase 1b/2 Fixed-dose Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia Posted on February 19, 2019 by tsuperadmin -
NCT01722487 – Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Posted on February 19, 2019 by tsuperadmin -
NCT00270049 – The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia Posted on October 20, 2015 by tsuperadmin -
The YODA Project